The UK government, private foundations and major pharma firms have opened the BARBARA platform, a virtual registry that unites 180 existing research databases and population studies. The name—Brain Ageing Registry for Biomarkers, Access to trials, Research and Adoption—honours Dame Barbara Windsor, who died of Alzheimer’s in 2020. James Bethell, former innovation minister, chairs the initiative. The platform intends to speed recruitment for dementia trials and position Britain as a prime destination for life‑science investment.

Globally, 158 treatments are in 192 trials for Alzheimer’s and other dementias, yet only 173 English patients joined late‑stage, commercially sponsored studies in 2024‑25, a figure Bethell described as terrifyingly low. NICE’s recent decision that lecanemab and donanemab lack value for money has dampened confidence in the UK market. Viable recruitment can double trial economics, Bethell noted, and the registry’s pre‑screened cohort could enable studies that enrol patients with early or pre‑diagnosis biomarkers.

Bristol Myers Squibb’s senior vice‑president for Informatics said BARBARA would generate unique datasets that AI and machine‑learning models can interrogate, accelerating therapeutic development. By lowering the cost and time of recruitment, the registry could lure more pharma companies to locate early‑stage studies in Britain, boosting the sector’s earnings and easing pressure on the NHS. The precise investment figure remains unannounced but is expected later this year.